The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The inspection has concluded with four observations
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Subscribe To Our Newsletter & Stay Updated
